Completed Clinical Trials

For more information about the Heart Failure Network trials, please use the links provided. These links will open a new window to the National Institutes of Health website:

ATHENA-HF (Study of High-dose Spironolactone vs. Placebo Therapy in Acute Heart Failure)

Information as posted on

The ATHENA study is closed to enrollment and the database is locked.  Publication is pending.

The purpose of this study is to test if a high dose of spironolactone (commercial name Aldactone) given early during and episode of acute heart failure, when compared to placebo (a sugar pill), improves the symptoms and outcomes in persons with acute heart failure.  The study will enrolled 360 participants at 22 clinical centers in the United States.


CARRESS (CARdiorenal REScue Study in Acute Decompensated Heart Failure)

Information as posted on

The CARRESS study (N Engl J Med. 2012 Dec 13; 367(24): 2296-304) showed that for worsened renal function, and persistent congestion, the use of a stepped pharmacologic-therapy algorithm was superior to a strategy of ultrafiltration for the preservation of renal function at 96 hours, with a similar amount of weight loss with the two approaches. Ultrafiltration was associated with a higher rate of adverse events.

DOSE (Diuretic Optimization Strategies Evaluation in Acute Heart Failure)

Information as posted on

The DOSE study (N Eng J Med. 2011 Mar 3;364(9):797-805) showed that among patients with acute decompensated heart failure, there were no significant differences in patients’ global assessment of symptoms or in the change in renal function when diuretic therapy was administered by bolus as compared with continuous infusion or at a high dose as compared with a low dose.

EXACT-HF (Using Allopurinol to Relieve Symptoms in Patients With Heart Failure and High Uric Acid Levels)

Information as posted on

The EXACT study (Circ Heart Failure 2013; 6; 862-868) showed accumulating evidence to suggest that the potential efficacy and safety of Xanthine Oxidase inhibition in cardiovascular disease states, in general, and heart failure, in particular.

FIGHT (Functional Impact of GLP-1 for Heart Failure Treatment)

Information as posted on

Results of the FIGHT study were presented at the 2015 AHA Late Breaking Clinical Trial presentation.  The FIGHT study showed that the GLP-1 agonist liraglutide does not improve post-hospitalization clinical stability in patients with relatively advanced HF and reduced LVEF.  Larger studies are needed to establish the safety of liraglutide or other GLP-1 agonists for diabetes management or weight loss in patients with advanced HF.  Publication is pending.

IRONOUT (Oral Iron Repletion Effects On Oxygen Uptake in Heart Failure)

Information as posted on

The IRONOUT study has completed enrollment and the database is locked.  Publication is pending.


NEAT (Nitrate’s Effect on Activity Tolerance in Heart Failure With Preserved Ejection Fraction)

Information as posted on

The NEAT study (N Engl J Med 2015;373(24):2314-24) showed that, as compared to placebo, isosorbide mononitrate decreased daily activity levels and did not improve submaximal exercise capacity, quality-of-life scores or NT-proBNP levels in HFpEF patients.  In addition, patient worn “accelerometry” devices provide unique information about the impact of therapies on patients daily functional status.

PRESERVE (Study of Renal Denervation in Patients With Heart Failure)

Information as posted on

The PRESERVE study was terminated.

RELAX (PhosphodiesteRasE-5 Inhibition to Improve CLinical Status And EXercise Capacity in Diastolic Heart)

Information as posted on

The RELAX study (JAMA. 2013 Mar 27;309(12):1268-77) showed that among patients with HFPEF, phosphodiesterase-5 inhibition with administration of sildenafil for 24 weeks, compared with placebo, did not result in significant improvement in exercise capacity or clinical status.

ROSE-AHF (Renal Optimization Strategies Evaluation in Acute Heart Failure) and RED ROSE (Reliable Evaluation of Dyspnea in the Heart Failure Network ROSE Study)

Information as posted on

The ROSE studies (JAMA. 2013 Dec 18;310(23):2533-43) showed that in participants with acute heart failure and renal dysfunction, neither low-dose dopamine nor low-dose nesiritide enhanced decongestion or improved renal function when added to diuretic therapy.

SMMART (Effectiveness of Surgical Mitral Valve Repair Versus Medical Treatment for People With Significant Mitral Regurgitation and Non-ischemic Congestive Heart Failure)

Information as posted on

The SMMART study was terminated.